Company Filing History:
2 out of 50 
1 out of 66 
Years Active: 2024-2025
Title: Gordon Grant Welstead: Innovator in Cancer Immunotherapy
Introduction
Gordon Grant Welstead is a prominent inventor based in Cambridge, MA (US). He has made significant contributions to the field of cancer immunotherapy, holding 2 patents that focus on innovative methods and compositions for treatment.
Latest Patents
His latest patents include "Crispr-CPF1-related methods, compositions and components for cancer immunotherapy," which explores CRISPR/Cpf1-related compositions and methods for the treatment of cancer. Another notable patent is "HPV-specific binding molecules," which provides binding molecules, such as TCRs or antigen-binding fragments, that recognize or bind to human papillomavirus (HPV) 16, including HPV 16 E6 and HPV 16 E7. This patent also discusses engineered cells containing such binding molecules and methods of treatment involving their administration.
Career Highlights
Gordon has worked with leading companies in the biotechnology sector, including Editas Medicine, Inc. and Juno Therapeutics GmbH. His work has been instrumental in advancing the understanding and application of CRISPR technology in cancer treatment.
Collaborations
He has collaborated with notable professionals in the field, including Hariharan Jayaram and Tongyao Wang, contributing to a rich exchange of ideas and innovations.
Conclusion
Gordon Grant Welstead's work in cancer immunotherapy exemplifies the impact of innovative thinking in medicine. His patents and collaborations continue to pave the way for advancements in treatment options for patients.